Completed Clinical Trials

Interleukin-12 in Treating Patients With Cancer in the Abdomen

By April 24, 2017 No Comments

Condition

Anal Cancer|Colorectal Cancer|Gallbladder Cancer|Gastric Cancer|Pancreatic Cancer

Estimated Enrollment: 29

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: ID97-027|P30CA016672|MDA-ID-97027|NCI-T97-0034|CDR0000065681

Study First Received: November 1, 1999

Last Updated: July 27, 2012

Estimated Primary Completion Date: October 2001

 

Primary Outcome Measures:

Maximum Tolerated Dose (MTD) of Intraperitoneal Interleukin-12

Sponsors and Collaborators:

M.D. Anderson Cancer Center|National Cancer Institute (NCI)

Website Link: https://ClinicalTrials.gov/show/NCT00003046

Leave a Reply

Call Now